No Data
Axsome Therapeutics Analyst Ratings
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $180
Positive Prescription Trends and Sales Expansion Drive Buy Rating for Axsome Therapeutics
Cantor Fitzgerald Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $121
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
Ladenburg Thalmann Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $175